Reactome | LAG3 (CD233) binds MHC II

LAG3 (CD233) binds MHC II

Stable Identifier

R-HSA-8856157

Type

Reaction [binding]

Species

Homo sapiens

Compartment

plasma membrane

ReviewStatus

5/5

Locations in the PathwayBrowser

Expand all

General

SBML | | PDF

SVG | | PPTX | SBGN

Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Melanomas often express MHC II molecules along with tumor-associated and tumor-specific Ags, which could make these tumors detectable and elemintaed by the immune system. However the expression of MHC II molecules by melanoma cells has been instead associated with poor prognosis (Ruiter et al. 1991, Deffrennes et al. 2001, Ostmeier et al. 2001, Martins et al. 2009). The exact role that MHC II might have in melanoma progression is unclear; it was suggested that MHC II can be involved in the escape of melanoma cells from immune surveillance. Lymphocyte-activation gene 3 (LAG3) belongs to Ig superfamily and is expressed by various subsets of tumor-infiltrating leukocytes. LAG3 is a natural ligand for MHC II and binds MHC II with a much higher avidity than CD4. LAG3 protects MHC II positive melanoma cells from apoptosis. Hemon et al proposes that LAG3-MHC II molecular interaction as a novel pathway enabling melanoma cells not only to escape immune attack but also to counter drug effects and to survive (Hemon et al. 2011).

Literature References

PubMed ID	Title	Journal	Year
21441454	MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis Charron, D, Brignone, C, Ramgolam, K, Triebel, F, Michel, L, Aoudjit, F, Bachelez, H, Al-Daccak, R, Viguier, M, Jean-Louis, F, Hemon, P	J. Immunol.	2011